Open AccessThalidomide induces complete remission of advanced hepatocellular carcinoma
Author(s) -
Chien ChengHung,
Chien RongNan
Publication year - 2014
Publication title -
advances in digestive medicine
Language(s) - English
Resource type - Journals
ISSN - 2351-9800
DOI - 10.1016/j.aidm.2014.03.002
Subject(s) - medicine , thalidomide , hepatocellular carcinoma , sorafenib , cirrhosis , hccs , transcatheter arterial chemoembolization , oncology , gastroenterology , complete remission , chemotherapy , carcinoma , neovascularization , radiology , surgery , angiogenesis , multiple myeloma
Summary Hepatocellular carcinoma (HCC) is one of the most prevalent human cancers in the world, but its prognosis is extremely poor. HCC is considered a hypervascular tumor. Thalidomide, which has been known to inhibit growth factor‐induced neovascularization, is a convenient alternative to target therapy such as sorafenib. We report a 65‐year‐old male patient with alcoholic liver cirrhosis that was diagnosed having multiple HCCs during surveillance. The patient was assessed as inoperable and unsuited for transhepatic arterial chemoembolization or systemic chemotherapy. After discussing the therapeutic alternatives, he decided to receive low‐dose thalidomide (100 mg daily) therapy. Fortunately, follow‐up liver biochemical tests, serum α‐fetoprotein level, and dynamic computed tomography showed complete remission of the HCCs 4.5 months after thalidomide treatment and this was documented for more than 22 months without evidence of tumor recurrence.